-+ 0.00%
-+ 0.00%
-+ 0.00%

RedHill Biopharma Highlights Growth Opportunities Following Talicia Divestiture, Portfolio Expansion

Benzinga·11/17/2026 14:26:16
Diffusion vocale

 RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that Guy Goldberg, Chief Business Officer of RedHill Biopharma, participated in a Virtual Investor "What This Means" segment.

During the interview, Mr. Goldberg discussed the strategic evolution of RedHill's business following the successful execution of two strategic transactions with mid-size pharma companies, the divestiture of Talicia and the acquisition of commercialization rights to Rebyota® and Clenpiq®, highlighting the Company's disciplined approach to capital allocation and its transition toward a broader, revenue-generating commercial specialty pharma growth business. The discussion explored the opportunities to accelerate growth across the expanded commercial GI portfolio by leveraging the Company's existing lean infrastructure, physician relationships and established market demand, as well as ongoing execution of a roll up strategy to build upon this foundation through additional complementary products. Mr. Goldberg also addressed RedHill's priorities for the coming quarters and how disciplined commercial execution, portfolio expansion and improved operating economics could support the Company's commercial growth strategy and shareholder value.